

## Haynes Boone Advises Oramed Through Transformative Transaction with Lifeward

---

January 13, 2026 Rick Werner, Simin Sun, Alla Digilova, Jennifer Kreick, Sam Lichtman, Jeffrey Wolfson, Cheyenne Karp, Brent Duddles, Lisa Vasek

---

**PRACTICES** Tax, Healthcare and Life Sciences, Patent Prosecution and Counseling, Corporate, Capital Markets and Securities, Mergers and Acquisitions

---

Haynes Boone represented Oramed Pharmaceuticals Inc., a clinical-stage pharmaceutical company pioneering oral drug delivery solutions, in its strategic transaction with Lifeward Ltd., a revenue-generating medical robotics company. This deal integrates pharmaceutical technology with advanced rehabilitation systems, positioning Oramed as a significant shareholder and creating a diversified platform for growth in life sciences and healthcare technology.

The transaction involves the transfer of Oramed's proprietary oral drug delivery POD™ technology to Lifeward, granting Oramed a 49.9 percent beneficial ownership interest in Lifeward, alongside warrants upon the satisfaction of certain terms and conditions. Oramed also agreed to invest in Lifeward through a \$9 million senior secured convertible note and an additional milestone-based \$9 million senior secured convertible note, each with 100 percent warrant coverage.

Haynes Boone Capital Markets and Securities Co-Chair [Rick Werner](#), Mergers and Acquisitions Partner [Simin Sun](#) and Capital Markets and Securities Partner [Alla Digilova](#) led the team, with assistance from:

- Healthcare and Life Sciences Co-Chair [Jennifer Kreick](#)
- Business Planning and Tax Chair [Sam Lichtman](#)
- Patent Prosecution Chair [Jeff Wolfson](#)
- Corporate Associates [Cheyenne Karp](#), [Brent Duddles](#) and [Lisa Vasek](#)

“We were delighted to support Oramed in executing this transformative transaction,” said Werner. “Our group’s deep experience in life sciences, healthcare technology and strategic investments allowed us to deliver a seamless process and help Oramed achieve its vision of combining oral drug delivery innovation with Lifeward’s proven medical robotics business.”

Haynes Boone’s [Capital Markets and Securities Practice](#) advises on high-value public offerings, including IPOs, PIPEs, reverse mergers and dual listings. The team has led landmark deals across energy, tech, life sciences and financial services, including [one of the largest IPOs in LSE history](#) and [the first Nasdaq-LSE dual listing of this century](#). Clients rely on our cross-border experience and integrated counsel across major U.S., U.K. and global exchanges for securities transactions, compliance and REIT structuring.